Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 189.53M | 178.96M | 170.28M | 185.31M | 154.34M | 98.38M |
Gross Profit | 115.73M | 106.88M | 94.72M | 127.40M | 105.04M | 75.85M |
EBITDA | -119.04M | -128.76M | -189.27M | -167.98M | -193.34M | -144.34M |
Net Income | -141.84M | -159.49M | -225.25M | -142.46M | -205.61M | -139.64M |
Balance Sheet | ||||||
Total Assets | 510.85M | 539.38M | 661.13M | 856.62M | 923.34M | 1.12B |
Cash, Cash Equivalents and Short-Term Investments | 193.42M | 222.29M | 346.40M | 498.20M | 353.06M | 688.27M |
Total Debt | 86.90M | 89.39M | 229.43M | 108.00M | 111.74M | 107.86M |
Total Liabilities | 320.63M | 336.89M | 352.86M | 392.52M | 319.24M | 373.15M |
Stockholders Equity | 190.42M | 202.71M | 308.40M | 464.17M | 603.99M | 743.27M |
Cash Flow | ||||||
Free Cash Flow | -88.75M | -98.88M | -167.02M | -200.29M | -254.47M | -168.49M |
Operating Cash Flow | -85.34M | -95.21M | -156.32M | -183.94M | -192.73M | -149.68M |
Investing Cash Flow | 58.86M | 77.79M | 129.65M | 2.90M | 181.21M | -117.04M |
Financing Cash Flow | 5.65M | 241.00K | 2.25M | 132.26M | 27.15M | 293.59M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $1.74B | ― | -60.96% | ― | 8.61% | 35.36% | |
59 Neutral | £5.93B | 9.05 | -57.69% | 4.70% | 15.15% | -8.16% | |
58 Neutral | $1.64B | ― | -5.78% | ― | 25.50% | 64.63% | |
48 Neutral | $774.43M | ― | -93.70% | ― | ― | -25.83% | |
48 Neutral | $584.39M | ― | -51.85% | ― | 11070.12% | 32.07% | |
42 Neutral | $1.47B | ― | -69.30% | ― | ― | -68.13% | |
42 Neutral | $971.07M | ― | -51.85% | ― | ― | 0.71% |
On June 10, 2025, Adaptive Biotechnologies held its annual shareholders meeting, where three proposals were voted on. These included the election of Chad Robins as a Class III director, an advisory vote on executive compensation for 2024, and the ratification of Ernst & Young LLP as the independent public accounting firm for 2025. All proposals were approved with significant support, reflecting strong shareholder confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (ADPT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Adaptive Biotechnologies stock, see the ADPT Stock Forecast page.